Sign in

NCT07923773Not yet recruitingPhase 2

Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201

Source: ClinicalTrials.gov · Last updated 6 Nov 2026

Brief summary (registry, in English)

The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have completed treatment in the CDDY391A12201 core study.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
88 (estimated)
First submitted
2 Nov 2026
Start date
10 Feb 2027
Primary completion date
12 Dec 2029
Lead sponsor
Novartis Pharmaceuticals
NCT number
NCT07923773

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 88
  • From 10 Feb 2027 to the primary completion date, 12 Dec 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participants taking other prohibited therapies, including but not limited to, high-potency opioids.
  • Received live attenuated vaccines 4 weeks prior to baseline or anticipated during the study or within 4 weeks of stopping the study drug.

Other illness

  • Any active viral, bacterial or other infections at the time of extension study entry or history of recurrent clinically significant infection or of recurrent bacterial infections.

Other

  • Women of childbearing potential unwilling to use protocol specified method of contraception.
  • Sexually active males unwilling to use a condom during intercourse while taking study treatment and for at least 28 days after stopping study treatment are excluded.
    • Other protocol-defined inclusion/exclusion criteria may apply.

Who the study is looking for

  • Participants must have completed study treatment in CDDY391A12201 and must not meet any treatment discontinuation criteria of the core study at the time of OLE enrollment.

Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.